Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3674995016 | Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3674997012 | Cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 mg prolonged-release oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has manufactured dose form | Prolonged-release oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator value | 1 (kwalificatiewaarde) | false | Inferred relationship | Some | 2 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator value | 1 (kwalificatiewaarde) | false | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Cyclopenthiazide (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Oxprenolol hydrochloride (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Oxprenolol hydrochloride (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator value | 250 | false | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 2 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mcg | false | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator value | 160 (kwalificatiewaarde) | false | Inferred relationship | Some | 2 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Cyclopenthiazide (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Is a | Cyclopenthiazide- and oxprenolol-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Count of base of active ingredient | 2 (kwalificatiewaarde) | false | Inferred relationship | Some | ||
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Is a | Product containing only cyclopenthiazide and oxprenolol in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Plays role | Diuretic therapeutic role | false | Inferred relationship | Some | ||
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Oxprenolol hydrochloride (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Oxprenolol hydrochloride (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Cyclopenthiazide (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mcg | true | Inferred relationship | Some | 2 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely cyclopenthiazide 250 microgram and oxprenolol hydrochloride 160 milligram/1 each prolonged-release oral tablet (clinical drug) | Has precise active ingredient | Cyclopenthiazide (substance) | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR